CG Oncology CGON Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.07M+666% | $4.04M+255% | $2.17M+218% | $551K-15.2% | $662K+22.8% | ||
| $132.9M+43.9% | $116.64M+42.1% | $113.48M+58.4% | $105.22M+65.0% | $92.36M+67.6% | ||
| $79.52M+86.2% | $73.53M+118% | $67.24M+169% | $52.62M+183% | $42.7M+214% | ||
| $220.03M— | $194.81M— | $182.3M— | $157.84M— | —— | ||
| -$214.96M-59.9% | -$190.77M-66.4% | -$180.12M-87.7% | -$157.29M-92.5% | -$134.4M-97.1% | ||
| -4,239%+16,063pp | -4,722.1%+5,345pp | -8,285.3%+5,746pp | -28,546.1%-15,974pp | -20,302.3%-7,651pp | ||
| $28.21M-2.2% | $29.78M+11.8% | $28.64M+23.6% | $29.21M+66.3% | $28.84M+155% | ||
| -$186.75M-76.9% | -$161M-82.9% | -$151.48M-108% | -$128.08M-99.6% | -$105.56M-85.6% | ||
| -3,682.6%+12,263pp | -3,985%+3,744pp | -6,968%+3,675pp | -23,245.2%-13,375pp | -15,945.2%-5,394pp | ||
| -$2.33-54.3% | -$2.07-45.8% | -$2.04+62.3% | -$1.77+80.6% | -$1.51+88.2% | ||
| -$212.7M-58.3% | -$189.33M-65.2% | -$179.53M-87.1% | -$157.09M-92.3% | -$134.35M-97.1% | ||
| -4,194.4%+16,100pp | -4,686.4%+5,378pp | -8,257.9%+5,768pp | -28,509.6%-15,940pp | -20,294.4%-7,646pp | ||
| -$214.96M-59.9% | -$190.77M-66.4% | -$180.12M-87.7% | -$157.29M-92.5% | -$134.4M-97.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does CG Oncology's income statement data come from?
- Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.